nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Carboplatin—urinary bladder cancer	0.153	0.225	CbGbCtD
Eprosartan—ABCC2—Cisplatin—urinary bladder cancer	0.131	0.192	CbGbCtD
Eprosartan—ABCC2—Etoposide—urinary bladder cancer	0.129	0.189	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—urinary bladder cancer	0.0877	0.129	CbGbCtD
Eprosartan—ABCC2—Methotrexate—urinary bladder cancer	0.085	0.125	CbGbCtD
Eprosartan—CYP2C9—Fluorouracil—urinary bladder cancer	0.0518	0.076	CbGbCtD
Eprosartan—CYP2C9—Cisplatin—urinary bladder cancer	0.044	0.0646	CbGbCtD
Eprosartan—Losartan—UGT2B7—urinary bladder cancer	0.00755	1	CrCbGaD
Eprosartan—CYP2C9—urine—urinary bladder cancer	0.00534	0.169	CbGeAlD
Eprosartan—AGTR1—prostate gland—urinary bladder cancer	0.00398	0.126	CbGeAlD
Eprosartan—AGTR1—epithelium—urinary bladder cancer	0.00293	0.0927	CbGeAlD
Eprosartan—ABCC2—prostate gland—urinary bladder cancer	0.00288	0.0912	CbGeAlD
Eprosartan—AGTR1—smooth muscle tissue—urinary bladder cancer	0.00282	0.0893	CbGeAlD
Eprosartan—AGTR1—renal system—urinary bladder cancer	0.00271	0.086	CbGeAlD
Eprosartan—AGTR1—female reproductive system—urinary bladder cancer	0.00217	0.0688	CbGeAlD
Eprosartan—AGTR1—vagina—urinary bladder cancer	0.00197	0.0623	CbGeAlD
Eprosartan—ABCC2—renal system—urinary bladder cancer	0.00196	0.0621	CbGeAlD
Eprosartan—ABCC2—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00181	0.234	CbGpPWpGaD
Eprosartan—ABCC2—female reproductive system—urinary bladder cancer	0.00157	0.0498	CbGeAlD
Eprosartan—AGTR1—lymph node—urinary bladder cancer	0.00127	0.0403	CbGeAlD
Eprosartan—CYP2C9—female reproductive system—urinary bladder cancer	0.00105	0.0332	CbGeAlD
Eprosartan—ABCC2—lymph node—urinary bladder cancer	0.000919	0.0291	CbGeAlD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000512	0.0661	CbGpPWpGaD
Eprosartan—CYP2C9—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.000367	0.0474	CbGpPWpGaD
Eprosartan—Angina pectoris—Epirubicin—urinary bladder cancer	0.000315	0.00116	CcSEcCtD
Eprosartan—Anorexia—Etoposide—urinary bladder cancer	0.000312	0.00115	CcSEcCtD
Eprosartan—Diarrhoea—Thiotepa—urinary bladder cancer	0.000312	0.00115	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000311	0.00114	CcSEcCtD
Eprosartan—Decreased appetite—Cisplatin—urinary bladder cancer	0.000311	0.00114	CcSEcCtD
Eprosartan—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000311	0.00114	CcSEcCtD
Eprosartan—Bronchitis—Epirubicin—urinary bladder cancer	0.000311	0.00114	CcSEcCtD
Eprosartan—Depression—Methotrexate—urinary bladder cancer	0.000307	0.00113	CcSEcCtD
Eprosartan—Hypotension—Etoposide—urinary bladder cancer	0.000306	0.00113	CcSEcCtD
Eprosartan—Gastritis—Doxorubicin—urinary bladder cancer	0.000306	0.00113	CcSEcCtD
Eprosartan—Pain—Cisplatin—urinary bladder cancer	0.000306	0.00112	CcSEcCtD
Eprosartan—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000305	0.00112	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000305	0.00112	CcSEcCtD
Eprosartan—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000303	0.00112	CcSEcCtD
Eprosartan—Renal failure—Methotrexate—urinary bladder cancer	0.000302	0.00111	CcSEcCtD
Eprosartan—Dizziness—Thiotepa—urinary bladder cancer	0.000302	0.00111	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.0003	0.0011	CcSEcCtD
Eprosartan—Urticaria—Fluorouracil—urinary bladder cancer	0.0003	0.0011	CcSEcCtD
Eprosartan—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000299	0.0011	CcSEcCtD
Eprosartan—Asthma—Doxorubicin—urinary bladder cancer	0.000299	0.0011	CcSEcCtD
Eprosartan—Pollakiuria—Epirubicin—urinary bladder cancer	0.000298	0.0011	CcSEcCtD
Eprosartan—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000298	0.0011	CcSEcCtD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000298	0.0385	CbGpPWpGaD
Eprosartan—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000295	0.00108	CcSEcCtD
Eprosartan—Paraesthesia—Etoposide—urinary bladder cancer	0.000294	0.00108	CcSEcCtD
Eprosartan—Haematuria—Methotrexate—urinary bladder cancer	0.000293	0.00108	CcSEcCtD
Eprosartan—Dyspnoea—Etoposide—urinary bladder cancer	0.000292	0.00107	CcSEcCtD
Eprosartan—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000291	0.00107	CcSEcCtD
Eprosartan—Somnolence—Etoposide—urinary bladder cancer	0.000291	0.00107	CcSEcCtD
Eprosartan—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000291	0.00107	CcSEcCtD
Eprosartan—Epistaxis—Methotrexate—urinary bladder cancer	0.00029	0.00107	CcSEcCtD
Eprosartan—Vomiting—Thiotepa—urinary bladder cancer	0.00029	0.00107	CcSEcCtD
Eprosartan—Rash—Thiotepa—urinary bladder cancer	0.000288	0.00106	CcSEcCtD
Eprosartan—Bronchitis—Doxorubicin—urinary bladder cancer	0.000287	0.00106	CcSEcCtD
Eprosartan—Dermatitis—Thiotepa—urinary bladder cancer	0.000287	0.00106	CcSEcCtD
Eprosartan—Headache—Thiotepa—urinary bladder cancer	0.000286	0.00105	CcSEcCtD
Eprosartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.000285	0.0368	CbGpPWpGaD
Eprosartan—Decreased appetite—Etoposide—urinary bladder cancer	0.000285	0.00105	CcSEcCtD
Eprosartan—Renal failure—Epirubicin—urinary bladder cancer	0.000283	0.00104	CcSEcCtD
Eprosartan—Body temperature increased—Cisplatin—urinary bladder cancer	0.000283	0.00104	CcSEcCtD
Eprosartan—Fatigue—Etoposide—urinary bladder cancer	0.000282	0.00104	CcSEcCtD
Eprosartan—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000282	0.00104	CcSEcCtD
Eprosartan—Constipation—Etoposide—urinary bladder cancer	0.00028	0.00103	CcSEcCtD
Eprosartan—Pain—Etoposide—urinary bladder cancer	0.00028	0.00103	CcSEcCtD
Eprosartan—Conjunctivitis—Epirubicin—urinary bladder cancer	0.00028	0.00103	CcSEcCtD
Eprosartan—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00028	0.00103	CcSEcCtD
Eprosartan—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000278	0.00102	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000278	0.00102	CcSEcCtD
Eprosartan—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000276	0.00102	CcSEcCtD
Eprosartan—Asthenia—Gemcitabine—urinary bladder cancer	0.000275	0.00101	CcSEcCtD
Eprosartan—Haematuria—Epirubicin—urinary bladder cancer	0.000275	0.00101	CcSEcCtD
Eprosartan—Pharyngitis—Methotrexate—urinary bladder cancer	0.000274	0.00101	CcSEcCtD
Eprosartan—Epistaxis—Epirubicin—urinary bladder cancer	0.000272	0.000999	CcSEcCtD
Eprosartan—Pruritus—Gemcitabine—urinary bladder cancer	0.000271	0.000998	CcSEcCtD
Eprosartan—Nausea—Thiotepa—urinary bladder cancer	0.000271	0.000996	CcSEcCtD
Eprosartan—Sinusitis—Epirubicin—urinary bladder cancer	0.00027	0.000993	CcSEcCtD
Eprosartan—Feeling abnormal—Etoposide—urinary bladder cancer	0.00027	0.000993	CcSEcCtD
Eprosartan—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00027	0.000991	CcSEcCtD
Eprosartan—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000268	0.000985	CcSEcCtD
Eprosartan—Pruritus—Fluorouracil—urinary bladder cancer	0.000267	0.000981	CcSEcCtD
Eprosartan—Visual impairment—Methotrexate—urinary bladder cancer	0.000266	0.000979	CcSEcCtD
Eprosartan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000263	0.000969	CcSEcCtD
Eprosartan—Bradycardia—Epirubicin—urinary bladder cancer	0.000263	0.000968	CcSEcCtD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000263	0.0339	CbGpPWpGaD
Eprosartan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000263	0.000965	CcSEcCtD
Eprosartan—Renal failure—Doxorubicin—urinary bladder cancer	0.000262	0.000963	CcSEcCtD
Eprosartan—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000261	0.00096	CcSEcCtD
Eprosartan—Urticaria—Etoposide—urinary bladder cancer	0.00026	0.000957	CcSEcCtD
Eprosartan—Rhinitis—Epirubicin—urinary bladder cancer	0.000259	0.000953	CcSEcCtD
Eprosartan—Abdominal pain—Etoposide—urinary bladder cancer	0.000259	0.000952	CcSEcCtD
Eprosartan—Body temperature increased—Etoposide—urinary bladder cancer	0.000259	0.000952	CcSEcCtD
Eprosartan—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000259	0.000952	CcSEcCtD
Eprosartan—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000259	0.000952	CcSEcCtD
Eprosartan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000258	0.000949	CcSEcCtD
Eprosartan—Tinnitus—Methotrexate—urinary bladder cancer	0.000258	0.000947	CcSEcCtD
Eprosartan—Asthenia—Cisplatin—urinary bladder cancer	0.000257	0.000943	CcSEcCtD
Eprosartan—Pharyngitis—Epirubicin—urinary bladder cancer	0.000257	0.000943	CcSEcCtD
Eprosartan—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000255	0.000936	CcSEcCtD
Eprosartan—Haematuria—Doxorubicin—urinary bladder cancer	0.000254	0.000934	CcSEcCtD
Eprosartan—Epistaxis—Doxorubicin—urinary bladder cancer	0.000251	0.000924	CcSEcCtD
Eprosartan—Sinusitis—Doxorubicin—urinary bladder cancer	0.00025	0.000919	CcSEcCtD
Eprosartan—Dizziness—Fluorouracil—urinary bladder cancer	0.000249	0.000917	CcSEcCtD
Eprosartan—Visual impairment—Epirubicin—urinary bladder cancer	0.000249	0.000916	CcSEcCtD
Eprosartan—Chills—Methotrexate—urinary bladder cancer	0.000248	0.000911	CcSEcCtD
Eprosartan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000245	0.0009	CcSEcCtD
Eprosartan—Vomiting—Gemcitabine—urinary bladder cancer	0.000244	0.000897	CcSEcCtD
Eprosartan—Bradycardia—Doxorubicin—urinary bladder cancer	0.000243	0.000895	CcSEcCtD
Eprosartan—Rash—Gemcitabine—urinary bladder cancer	0.000242	0.00089	CcSEcCtD
Eprosartan—Dermatitis—Gemcitabine—urinary bladder cancer	0.000242	0.000889	CcSEcCtD
Eprosartan—Hypersensitivity—Etoposide—urinary bladder cancer	0.000241	0.000888	CcSEcCtD
Eprosartan—Tinnitus—Epirubicin—urinary bladder cancer	0.000241	0.000886	CcSEcCtD
Eprosartan—Headache—Gemcitabine—urinary bladder cancer	0.00024	0.000884	CcSEcCtD
Eprosartan—Vomiting—Fluorouracil—urinary bladder cancer	0.00024	0.000882	CcSEcCtD
Eprosartan—Rhinitis—Doxorubicin—urinary bladder cancer	0.00024	0.000882	CcSEcCtD
Eprosartan—Rash—Fluorouracil—urinary bladder cancer	0.000238	0.000875	CcSEcCtD
Eprosartan—Dermatitis—Fluorouracil—urinary bladder cancer	0.000238	0.000874	CcSEcCtD
Eprosartan—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000237	0.000873	CcSEcCtD
Eprosartan—Headache—Fluorouracil—urinary bladder cancer	0.000236	0.000869	CcSEcCtD
Eprosartan—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000236	0.000866	CcSEcCtD
Eprosartan—Asthenia—Etoposide—urinary bladder cancer	0.000235	0.000864	CcSEcCtD
Eprosartan—Back pain—Methotrexate—urinary bladder cancer	0.000233	0.000855	CcSEcCtD
Eprosartan—Chills—Epirubicin—urinary bladder cancer	0.000232	0.000853	CcSEcCtD
Eprosartan—Pruritus—Etoposide—urinary bladder cancer	0.000232	0.000852	CcSEcCtD
Eprosartan—Visual impairment—Doxorubicin—urinary bladder cancer	0.00023	0.000848	CcSEcCtD
Eprosartan—Nausea—Gemcitabine—urinary bladder cancer	0.000228	0.000838	CcSEcCtD
Eprosartan—Vomiting—Cisplatin—urinary bladder cancer	0.000227	0.000836	CcSEcCtD
Eprosartan—Rash—Cisplatin—urinary bladder cancer	0.000225	0.000829	CcSEcCtD
Eprosartan—Dermatitis—Cisplatin—urinary bladder cancer	0.000225	0.000828	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000225	0.029	CbGpPWpGaD
Eprosartan—Diarrhoea—Etoposide—urinary bladder cancer	0.000224	0.000824	CcSEcCtD
Eprosartan—Nausea—Fluorouracil—urinary bladder cancer	0.000224	0.000824	CcSEcCtD
Eprosartan—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000223	0.00082	CcSEcCtD
Eprosartan—Tinnitus—Doxorubicin—urinary bladder cancer	0.000223	0.00082	CcSEcCtD
Eprosartan—Flatulence—Epirubicin—urinary bladder cancer	0.000222	0.000815	CcSEcCtD
Eprosartan—Tension—Epirubicin—urinary bladder cancer	0.000221	0.000812	CcSEcCtD
Eprosartan—Nervousness—Epirubicin—urinary bladder cancer	0.000219	0.000804	CcSEcCtD
Eprosartan—Back pain—Epirubicin—urinary bladder cancer	0.000218	0.0008	CcSEcCtD
Eprosartan—Malaise—Methotrexate—urinary bladder cancer	0.000217	0.000797	CcSEcCtD
Eprosartan—Dizziness—Etoposide—urinary bladder cancer	0.000217	0.000797	CcSEcCtD
Eprosartan—Muscle spasms—Epirubicin—urinary bladder cancer	0.000216	0.000796	CcSEcCtD
Eprosartan—Vertigo—Methotrexate—urinary bladder cancer	0.000216	0.000794	CcSEcCtD
Eprosartan—Chills—Doxorubicin—urinary bladder cancer	0.000215	0.000789	CcSEcCtD
Eprosartan—Nausea—Cisplatin—urinary bladder cancer	0.000212	0.000781	CcSEcCtD
Eprosartan—Cough—Methotrexate—urinary bladder cancer	0.00021	0.000772	CcSEcCtD
Eprosartan—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000209	0.000768	CcSEcCtD
Eprosartan—Vomiting—Etoposide—urinary bladder cancer	0.000208	0.000766	CcSEcCtD
Eprosartan—Rash—Etoposide—urinary bladder cancer	0.000207	0.00076	CcSEcCtD
Eprosartan—Dermatitis—Etoposide—urinary bladder cancer	0.000206	0.000759	CcSEcCtD
Eprosartan—Headache—Etoposide—urinary bladder cancer	0.000205	0.000755	CcSEcCtD
Eprosartan—Flatulence—Doxorubicin—urinary bladder cancer	0.000205	0.000754	CcSEcCtD
Eprosartan—Myalgia—Methotrexate—urinary bladder cancer	0.000205	0.000753	CcSEcCtD
Eprosartan—Chest pain—Methotrexate—urinary bladder cancer	0.000205	0.000753	CcSEcCtD
Eprosartan—Arthralgia—Methotrexate—urinary bladder cancer	0.000205	0.000753	CcSEcCtD
Eprosartan—Tension—Doxorubicin—urinary bladder cancer	0.000204	0.000751	CcSEcCtD
Eprosartan—Malaise—Epirubicin—urinary bladder cancer	0.000203	0.000746	CcSEcCtD
Eprosartan—Discomfort—Methotrexate—urinary bladder cancer	0.000202	0.000744	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—urinary bladder cancer	0.000202	0.000744	CcSEcCtD
Eprosartan—Vertigo—Epirubicin—urinary bladder cancer	0.000202	0.000743	CcSEcCtD
Eprosartan—Syncope—Epirubicin—urinary bladder cancer	0.000202	0.000742	CcSEcCtD
Eprosartan—Back pain—Doxorubicin—urinary bladder cancer	0.000201	0.000741	CcSEcCtD
Eprosartan—Muscle spasms—Doxorubicin—urinary bladder cancer	0.0002	0.000736	CcSEcCtD
Eprosartan—Palpitations—Epirubicin—urinary bladder cancer	0.000199	0.000731	CcSEcCtD
Eprosartan—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000198	0.000727	CcSEcCtD
Eprosartan—Cough—Epirubicin—urinary bladder cancer	0.000196	0.000722	CcSEcCtD
Eprosartan—Nausea—Etoposide—urinary bladder cancer	0.000195	0.000716	CcSEcCtD
Eprosartan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000193	0.00071	CcSEcCtD
Eprosartan—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000192	0.000707	CcSEcCtD
Eprosartan—Myalgia—Epirubicin—urinary bladder cancer	0.000192	0.000704	CcSEcCtD
Eprosartan—Chest pain—Epirubicin—urinary bladder cancer	0.000192	0.000704	CcSEcCtD
Eprosartan—Arthralgia—Epirubicin—urinary bladder cancer	0.000192	0.000704	CcSEcCtD
Eprosartan—Anxiety—Epirubicin—urinary bladder cancer	0.000191	0.000702	CcSEcCtD
Eprosartan—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00019	0.000698	CcSEcCtD
Eprosartan—Discomfort—Epirubicin—urinary bladder cancer	0.000189	0.000696	CcSEcCtD
Eprosartan—Malaise—Doxorubicin—urinary bladder cancer	0.000188	0.00069	CcSEcCtD
Eprosartan—Dry mouth—Epirubicin—urinary bladder cancer	0.000187	0.000689	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—urinary bladder cancer	0.000187	0.000688	CcSEcCtD
Eprosartan—Anorexia—Methotrexate—urinary bladder cancer	0.000187	0.000688	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—urinary bladder cancer	0.000187	0.000687	CcSEcCtD
Eprosartan—Palpitations—Doxorubicin—urinary bladder cancer	0.000184	0.000677	CcSEcCtD
Eprosartan—Hypotension—Methotrexate—urinary bladder cancer	0.000183	0.000674	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000183	0.000673	CcSEcCtD
Eprosartan—Cough—Doxorubicin—urinary bladder cancer	0.000182	0.000668	CcSEcCtD
Eprosartan—Shock—Epirubicin—urinary bladder cancer	0.000181	0.000664	CcSEcCtD
Eprosartan—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00018	0.000661	CcSEcCtD
Eprosartan—Tachycardia—Epirubicin—urinary bladder cancer	0.000179	0.000659	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000179	0.000657	CcSEcCtD
Eprosartan—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000178	0.000653	CcSEcCtD
Eprosartan—Insomnia—Methotrexate—urinary bladder cancer	0.000177	0.000653	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000177	0.0229	CbGpPWpGaD
Eprosartan—Arthralgia—Doxorubicin—urinary bladder cancer	0.000177	0.000652	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—urinary bladder cancer	0.000177	0.000652	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—urinary bladder cancer	0.000177	0.000652	CcSEcCtD
Eprosartan—Anxiety—Doxorubicin—urinary bladder cancer	0.000177	0.00065	CcSEcCtD
Eprosartan—Paraesthesia—Methotrexate—urinary bladder cancer	0.000176	0.000648	CcSEcCtD
Eprosartan—Discomfort—Doxorubicin—urinary bladder cancer	0.000175	0.000644	CcSEcCtD
Eprosartan—Anorexia—Epirubicin—urinary bladder cancer	0.000175	0.000644	CcSEcCtD
Eprosartan—Dyspnoea—Methotrexate—urinary bladder cancer	0.000175	0.000643	CcSEcCtD
Eprosartan—Somnolence—Methotrexate—urinary bladder cancer	0.000174	0.000641	CcSEcCtD
Eprosartan—Dry mouth—Doxorubicin—urinary bladder cancer	0.000173	0.000637	CcSEcCtD
Eprosartan—Dyspepsia—Methotrexate—urinary bladder cancer	0.000173	0.000635	CcSEcCtD
Eprosartan—Hypotension—Epirubicin—urinary bladder cancer	0.000172	0.000631	CcSEcCtD
Eprosartan—Decreased appetite—Methotrexate—urinary bladder cancer	0.000171	0.000627	CcSEcCtD
Eprosartan—Fatigue—Methotrexate—urinary bladder cancer	0.000169	0.000622	CcSEcCtD
Eprosartan—Pain—Methotrexate—urinary bladder cancer	0.000168	0.000617	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000167	0.000615	CcSEcCtD
Eprosartan—Shock—Doxorubicin—urinary bladder cancer	0.000167	0.000615	CcSEcCtD
Eprosartan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000166	0.000612	CcSEcCtD
Eprosartan—Insomnia—Epirubicin—urinary bladder cancer	0.000166	0.000611	CcSEcCtD
Eprosartan—Tachycardia—Doxorubicin—urinary bladder cancer	0.000166	0.00061	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000165	0.0213	CbGpPWpGaD
Eprosartan—Paraesthesia—Epirubicin—urinary bladder cancer	0.000165	0.000606	CcSEcCtD
Eprosartan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000164	0.000604	CcSEcCtD
Eprosartan—Dyspnoea—Epirubicin—urinary bladder cancer	0.000164	0.000602	CcSEcCtD
Eprosartan—Somnolence—Epirubicin—urinary bladder cancer	0.000163	0.0006	CcSEcCtD
Eprosartan—Anorexia—Doxorubicin—urinary bladder cancer	0.000162	0.000596	CcSEcCtD
Eprosartan—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000162	0.000595	CcSEcCtD
Eprosartan—Dyspepsia—Epirubicin—urinary bladder cancer	0.000162	0.000594	CcSEcCtD
Eprosartan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00016	0.00059	CcSEcCtD
Eprosartan—Decreased appetite—Epirubicin—urinary bladder cancer	0.00016	0.000587	CcSEcCtD
Eprosartan—Hypotension—Doxorubicin—urinary bladder cancer	0.000159	0.000584	CcSEcCtD
Eprosartan—Fatigue—Epirubicin—urinary bladder cancer	0.000158	0.000582	CcSEcCtD
Eprosartan—Constipation—Epirubicin—urinary bladder cancer	0.000157	0.000577	CcSEcCtD
Eprosartan—Pain—Epirubicin—urinary bladder cancer	0.000157	0.000577	CcSEcCtD
Eprosartan—Urticaria—Methotrexate—urinary bladder cancer	0.000156	0.000573	CcSEcCtD
Eprosartan—Abdominal pain—Methotrexate—urinary bladder cancer	0.000155	0.00057	CcSEcCtD
Eprosartan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000155	0.00057	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000155	0.000569	CcSEcCtD
Eprosartan—Insomnia—Doxorubicin—urinary bladder cancer	0.000154	0.000565	CcSEcCtD
Eprosartan—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000153	0.000561	CcSEcCtD
Eprosartan—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000151	0.000557	CcSEcCtD
Eprosartan—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000151	0.000556	CcSEcCtD
Eprosartan—Somnolence—Doxorubicin—urinary bladder cancer	0.000151	0.000555	CcSEcCtD
Eprosartan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00015	0.000552	CcSEcCtD
Eprosartan—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00015	0.00055	CcSEcCtD
Eprosartan—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000148	0.000543	CcSEcCtD
Eprosartan—Fatigue—Doxorubicin—urinary bladder cancer	0.000147	0.000539	CcSEcCtD
Eprosartan—Urticaria—Epirubicin—urinary bladder cancer	0.000146	0.000536	CcSEcCtD
Eprosartan—Constipation—Doxorubicin—urinary bladder cancer	0.000145	0.000534	CcSEcCtD
Eprosartan—Pain—Doxorubicin—urinary bladder cancer	0.000145	0.000534	CcSEcCtD
Eprosartan—Abdominal pain—Epirubicin—urinary bladder cancer	0.000145	0.000534	CcSEcCtD
Eprosartan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000145	0.000534	CcSEcCtD
Eprosartan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000145	0.000532	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000143	0.0184	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 trafficking events—CDH1—urinary bladder cancer	0.000142	0.0184	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000141	0.0182	CbGpPWpGaD
Eprosartan—Asthenia—Methotrexate—urinary bladder cancer	0.000141	0.000518	CcSEcCtD
Eprosartan—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00014	0.000515	CcSEcCtD
Eprosartan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000139	0.000511	CcSEcCtD
Eprosartan—Pruritus—Methotrexate—urinary bladder cancer	0.000139	0.000511	CcSEcCtD
Eprosartan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000135	0.000498	CcSEcCtD
Eprosartan—Urticaria—Doxorubicin—urinary bladder cancer	0.000135	0.000496	CcSEcCtD
Eprosartan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000134	0.000494	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000134	0.000494	CcSEcCtD
Eprosartan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000134	0.000494	CcSEcCtD
Eprosartan—Asthenia—Epirubicin—urinary bladder cancer	0.000132	0.000485	CcSEcCtD
Eprosartan—Pruritus—Epirubicin—urinary bladder cancer	0.00013	0.000478	CcSEcCtD
Eprosartan—Dizziness—Methotrexate—urinary bladder cancer	0.00013	0.000477	CcSEcCtD
Eprosartan—Diarrhoea—Epirubicin—urinary bladder cancer	0.000126	0.000462	CcSEcCtD
Eprosartan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000125	0.00046	CcSEcCtD
Eprosartan—Vomiting—Methotrexate—urinary bladder cancer	0.000125	0.000459	CcSEcCtD
Eprosartan—Rash—Methotrexate—urinary bladder cancer	0.000124	0.000455	CcSEcCtD
Eprosartan—Dermatitis—Methotrexate—urinary bladder cancer	0.000124	0.000455	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—FAS—urinary bladder cancer	0.000123	0.0159	CbGpPWpGaD
Eprosartan—Headache—Methotrexate—urinary bladder cancer	0.000123	0.000452	CcSEcCtD
Eprosartan—Asthenia—Doxorubicin—urinary bladder cancer	0.000122	0.000448	CcSEcCtD
Eprosartan—Dizziness—Epirubicin—urinary bladder cancer	0.000121	0.000447	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000121	0.0156	CbGpPWpGaD
Eprosartan—Pruritus—Doxorubicin—urinary bladder cancer	0.00012	0.000442	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—SRC—urinary bladder cancer	0.00012	0.0155	CbGpPWpGaD
Eprosartan—Vomiting—Epirubicin—urinary bladder cancer	0.000117	0.000429	CcSEcCtD
Eprosartan—Nausea—Methotrexate—urinary bladder cancer	0.000117	0.000429	CcSEcCtD
Eprosartan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000116	0.000428	CcSEcCtD
Eprosartan—Rash—Epirubicin—urinary bladder cancer	0.000116	0.000426	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000116	0.0149	CbGpPWpGaD
Eprosartan—Dermatitis—Epirubicin—urinary bladder cancer	0.000116	0.000425	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000115	0.0149	CbGpPWpGaD
Eprosartan—Headache—Epirubicin—urinary bladder cancer	0.000115	0.000423	CcSEcCtD
Eprosartan—Dizziness—Doxorubicin—urinary bladder cancer	0.000112	0.000413	CcSEcCtD
Eprosartan—Nausea—Epirubicin—urinary bladder cancer	0.000109	0.000401	CcSEcCtD
Eprosartan—Vomiting—Doxorubicin—urinary bladder cancer	0.000108	0.000397	CcSEcCtD
Eprosartan—Rash—Doxorubicin—urinary bladder cancer	0.000107	0.000394	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—urinary bladder cancer	0.000107	0.000394	CcSEcCtD
Eprosartan—Headache—Doxorubicin—urinary bladder cancer	0.000106	0.000391	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—EGFR—urinary bladder cancer	0.000105	0.0136	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—urinary bladder cancer	0.000101	0.000371	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—urinary bladder cancer	9.76e-05	0.0126	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	8.79e-05	0.0113	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	7.88e-05	0.0102	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	7.77e-05	0.01	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—urinary bladder cancer	7.54e-05	0.00973	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—CXCL8—urinary bladder cancer	7.51e-05	0.0097	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	7.47e-05	0.00964	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	7.47e-05	0.00964	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	7.37e-05	0.00951	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL2—urinary bladder cancer	7.18e-05	0.00927	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—NQO1—urinary bladder cancer	6.84e-05	0.00884	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	6.83e-05	0.00882	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	6.74e-05	0.0087	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	6.21e-05	0.00802	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	6.15e-05	0.00794	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	6.07e-05	0.00783	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—GSTP1—urinary bladder cancer	5.71e-05	0.00737	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	5.3e-05	0.00684	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—GSTM1—urinary bladder cancer	5.25e-05	0.00677	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TNF—urinary bladder cancer	5.23e-05	0.00675	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	5.2e-05	0.00671	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	4.49e-05	0.0058	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	4.09e-05	0.00528	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	4.04e-05	0.00521	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	3.72e-05	0.00481	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.66e-05	0.00472	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	3.27e-05	0.00422	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	3.17e-05	0.0041	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	3.06e-05	0.00395	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HDAC4—urinary bladder cancer	2.82e-05	0.00364	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	2.5e-05	0.00322	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.47e-05	0.00319	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	2.46e-05	0.00318	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	2.36e-05	0.00305	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GLI1—urinary bladder cancer	2.36e-05	0.00305	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	2.33e-05	0.00301	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	2.2e-05	0.00284	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.17e-05	0.0028	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	2.02e-05	0.00261	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.99e-05	0.00257	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	1.98e-05	0.00255	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCL8—urinary bladder cancer	1.9e-05	0.00245	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RBX1—urinary bladder cancer	1.62e-05	0.00209	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TSC1—urinary bladder cancer	1.52e-05	0.00196	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAG1—urinary bladder cancer	1.45e-05	0.00187	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	1.35e-05	0.00174	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NAT1—urinary bladder cancer	1.28e-05	0.00165	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	1.28e-05	0.00165	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.26e-05	0.00162	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.22e-05	0.00158	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—S100B—urinary bladder cancer	1.17e-05	0.00151	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	1.17e-05	0.00151	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.16e-05	0.00149	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RHOA—urinary bladder cancer	1.11e-05	0.00143	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.07e-05	0.00139	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.05e-05	0.00136	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.05e-05	0.00136	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL2—urinary bladder cancer	1.03e-05	0.00133	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	9.93e-06	0.00128	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—urinary bladder cancer	9.76e-06	0.00126	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	9.68e-06	0.00125	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL2—urinary bladder cancer	9.32e-06	0.0012	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TERT—urinary bladder cancer	9.29e-06	0.0012	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGFR3—urinary bladder cancer	8.52e-06	0.0011	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ESR1—urinary bladder cancer	8.28e-06	0.00107	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.76e-06	0.001	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TYMP—urinary bladder cancer	7.74e-06	0.000999	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.43e-06	0.00096	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CREBBP—urinary bladder cancer	7.26e-06	0.000937	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1—urinary bladder cancer	7.17e-06	0.000925	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—urinary bladder cancer	7.13e-06	0.000921	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NAT2—urinary bladder cancer	7e-06	0.000904	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KRAS—urinary bladder cancer	6.74e-06	0.00087	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RHOA—urinary bladder cancer	6.56e-06	0.000848	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB2—urinary bladder cancer	6.08e-06	0.000785	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—RRM2—urinary bladder cancer	6.04e-06	0.00078	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—urinary bladder cancer	5.76e-06	0.000744	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HRAS—urinary bladder cancer	5.73e-06	0.000739	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ENO2—urinary bladder cancer	5.59e-06	0.000722	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	5.59e-06	0.000722	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.56e-06	0.000718	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL2—urinary bladder cancer	5.51e-06	0.000711	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	5.43e-06	0.000701	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCND1—urinary bladder cancer	5.37e-06	0.000693	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.34e-06	0.00069	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—urinary bladder cancer	5.21e-06	0.000673	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.19e-06	0.000671	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTEN—urinary bladder cancer	5.18e-06	0.000669	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EP300—urinary bladder cancer	4.94e-06	0.000638	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SRC—urinary bladder cancer	4.81e-06	0.000621	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NQO1—urinary bladder cancer	4.51e-06	0.000582	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.37e-06	0.000565	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—urinary bladder cancer	4.31e-06	0.000556	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—urinary bladder cancer	4.21e-06	0.000544	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KRAS—urinary bladder cancer	3.98e-06	0.000514	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.82e-06	0.000493	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.76e-06	0.000486	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.64e-06	0.00047	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—urinary bladder cancer	3.54e-06	0.000457	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.5e-06	0.000451	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.46e-06	0.000446	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.46e-06	0.000446	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HRAS—urinary bladder cancer	3.38e-06	0.000437	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.31e-06	0.000427	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.25e-06	0.00042	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.05e-06	0.000394	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.48e-06	0.00032	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.38e-06	0.000307	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.95e-06	0.000252	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.7e-06	0.000219	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.62e-06	0.000209	CbGpPWpGaD
